GRCE

Grace Therapeutics (GRCE)

About Grace Therapeutics (GRCE)

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Details

Daily high

$2.16

Daily low

$2.10

Price at open

$2.13

52 Week High

$5.18

52 Week Low

$1.79

Market cap

34.5M

Dividend yield

0.00%

Volume

120,376

Avg. volume

245,946

P/E ratio

-4.41

Grace Therapeutics News